Influence of the CB1 cannabinoid receptors on the activity of the monoaminergic system in the behavioural tests in mice

Poleszak, Ewa; Wośko, Sylwia; Sławińska, Karolina; Wyska, Elżbieta; Szopa, Aleksandra; Doboszewska, Urszula; Właź, Piotr; Właź, Aleksandra; Dudka, Jarosław; Szponar, Jarosław; Serefko, Anna

doi:10.1016/j.brainresbull.2019.05.021

Cited by 12 publications

(10 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we should admit that such a bidirectional potentiation of the antidepressant action by cannabinoids had been observed before in our laboratory. The results of our previous studies demonstrated that oleamide and AM251 when administered at the sub-threshold concentrations in albino Swiss mice can potentiate the antidepressant activity of imipramine (15 mg/ kg), escitalopram (2 mg/kg), and reboxetine (2.5 mg/kg) [6]. They also enhanced the antidepressant-like properties of biometals (i.e.…”

Section: Discussionmentioning

confidence: 89%

“…Mice from the control groups were injected with either 1% aqueous solution of Tween and/or saline. The pre-treatment schedules and the tested doses were chosen on the basis of the literature data [10] and our previous experimental projects [6,11,12]. A standard volume of liquid dosage forms (i.e.…”

Section: Drugsmentioning

confidence: 99%

“…Knowing that cannabinoid (CB) receptor ligands are able to potentiate the activity of common antidepressants, i.e. the tricyclic imipramine, selective serotonine reuptake inhibitor-escitalopram, and selective inhibitor of noradrenaline reuptake-reboxetine [6], we wanted to check whether they can also affect the effects of other antidepressant drugs that have a little bit different biological targets, such as bupropion and moclobemide. Bupropion belongs to the dual acting antidepressant agents, and it acts via inhibition of reuptake of dopamine and noradrenaline.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Influence of the endocannabinoid system on the antidepressant activity of bupropion and moclobemide in the behavioural tests in mice

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background Though there are several classes of antidepressant drugs available on the pharmaceutical market, depression that affects globally over 320 million people is still undertreated. Scientists have made attempts to develop novel therapeutical strategies to maximize effectiveness of therapy and minimize undesired reactions. One of the ideas is use of either dual-action agents or combined administration of two substances that affect diverse neurotransmissions. Thus, we investigated whether the selected CB receptor ligands (oleamide, AM251, JWH133, and AM630) can have an impact on the activity of bupropion and moclobemide. Bupropion belongs to the dual acting drugs, whereas moclobemide is an inhibitor of monoamine oxidase. Methods The mice forced swim test and the tail suspension test were applied in order to determine the potential antidepressant-like activity, whereas the HPLC method was used in order to assess the brain concentrations of the tested antidepressants. Results An intraperitoneal injection of sub-effective doses of oleamide (5 mg/kg), AM251 (0.25 mg/kg), and AM630 (0.25 mg/kg) increased activity of bupropion (10 mg/kg) in both behavioural tests. Effects of moclobemide (1.5 mg/kg) were potentiated only by AM251. These results were not influenced by the hypo-or hyperlocomotion of animals. Conclusion The outcomes of the present study revealed that particularly activation or inhibition of the CB 1 receptor function may augment the antidepressant activity of bupropion, whereas only inhibition of the CB 1 receptor function manages to increase activity of moclobemide. Most probably, an interplay between CB receptor ligands and bupropion or moclobemide takes place at the cellular level.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Drugsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Influence of the endocannabinoid system on the antidepressant activity of bupropion and moclobemide in the behavioural tests in mice

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Interestingly, in multiple pre-clinical studies, agonists and antagonists/inverse agonists of CB 1 and CB 2 receptors exerted antidepressant effects in rodents. Moreover, we previously demonstrated that they managed to enhance the activity of conventional antidepressant drugs belonging to different pharmacological classes, such as imipramine, escitalopram, and reboxetine ( Poleszak et al, 2019 ). On the other hand, mice and rats with experimentally-induced depression as well as depressed patients and suicide victims present diverse abnormalities in the endocannabinoid system [for review see ( Poleszak et al, 2018 )].…”

Section: Discussionmentioning

confidence: 99%

O-1602, an Agonist of Atypical Cannabinoid Receptors GPR55, Reverses the Symptoms of Depression and Detrusor Overactivity in Rats Subjected to Corticosterone Treatment

et al. 2020

Self Cite

View full text Add to dashboard Cite

In view of the fact that GPR55 receptors are localized in brain areas implicated in the pathophysiology of depression, GPR55 gene expression is reduced in the dorsolateral prefrontal cortex of suicide victims, and GPR55 receptor agonism exerts an anxiolytic-like effect, GPR55 receptors have drawn our attention as a potential target in the treatment of mood disorders. Therefore, in the present study, we wanted to check whether a 7-day intravenous administration of O-1602 (0.25 mg/kg/day) – a phytocannabinoid-like analogue of cannabidiol that belongs to the agonists of GPR55 receptors, was able to reverse the corticosterone-induced depressive-like behavior accompanied by detrusor overactivity in female Wistar rats. Additionally, we tried to determine the influence of GPR55 stimulation on the bladder, hippocampal and urine levels of several biomarkers that play a role in the functioning of the urinary bladder and/or the pathophysiology of depression. Our experiments showed that O-1602 therapy improved signs of depression (measured by the forced swim test) and detrusor contractility (measured by conscious cystometry) in animals exposed to the corticosterone treatment. Moreover, the treatment reduced the oxidative damage in the urinary bladder and neuroinflammation (observed as the reduction of elevated levels of 3-NIT, MAL, and IL-1β, TNF-α, CRF, respectively). The O-1602 treatment also reversed the abnormal changes in the bladder, hippocampal or urine values of CGRP, OCT3, VAChT, BDNF, and NGF. The above-mentioned findings allow to suggest that in the future the modulation of atypical cannabinoid receptors GPR55 could have a potential role in the treatment of depression and overactive bladder.

show abstract

“…Several studies have suggested that the CB1 receptor and other components of the endocannabinoid system seem to be upregulated after chronic treatment with AD in mice submitted to homotypic stress (Hill et al, 2006a(Hill et al, , 2006b. Conversely, Poleszak et al (2019), have demonstrated that acute administration of AM251 potentiated the antidepressant-like effect of Esc in rats submitted to the forced swimming test. Herein, we observed an attenuation of antidepressant-like effect in the TST with repeated Esc and AM251 treatment under stress conditions.…”

Section: Discussionmentioning

confidence: 99%

The contribution of 5-HT1A receptors in improving plasticity and function of the brain

Aguiar¹

View full text Add to dashboard Cite

People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.• The final author version and the galley proof are versions of the publication after peer review.• The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal. CONTENTS CHAPTER 1 8 General introduction. CHAPTER 2 23The 5-HT1A receptor as a serotonergic target for neuroprotection in cerebral ischemia.CHAPTER 3 68 Activation of 5-HT1A postsynaptic receptors by NLX-101 results in functional recovery and an increase in neuroplasticity in mice with brain ischemia.CHAPTER 4 100 NLX-101, a biased 5-HT1A receptor agonist, improves pattern separation and stimulates neuroplasticity in aged rats. CHAPTER 5131 Involvement of the type-1 cannabinoid receptor (CB1) in the anti-stress and neuroplastic effects of antidepressants.

show abstract

Influence of the CB1 cannabinoid receptors on the activity of the monoaminergic system in the behavioural tests in mice

Cited by 12 publications

References 41 publications

Influence of the endocannabinoid system on the antidepressant activity of bupropion and moclobemide in the behavioural tests in mice

Influence of the endocannabinoid system on the antidepressant activity of bupropion and moclobemide in the behavioural tests in mice

O-1602, an Agonist of Atypical Cannabinoid Receptors GPR55, Reverses the Symptoms of Depression and Detrusor Overactivity in Rats Subjected to Corticosterone Treatment

The contribution of 5-HT1A receptors in improving plasticity and function of the brain

Contact Info

Product

Resources

About